{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T12:59:01Z","timestamp":1754485141164},"reference-count":24,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,8,10]]},"DOI":"10.7759\/cureus.17046","type":"journal-article","created":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T11:07:38Z","timestamp":1628593658000},"source":"Crossref","is-referenced-by-count":2,"title":["Hypocalcemia in a Patient With Metastatic Prostate Cancer From Denosumab Treatment"],"prefix":"10.7759","author":[{"given":"Sugam","family":"Gouli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jimmy","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anush","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffery","family":"Allerton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray F","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018, 68:394-424. 10.3322\/caac.21492","journal-title":"CA Cancer J Clin"},{"key":"ref2","article-title":"Management of skeletal-related events in patients with advanced prostate cancer and bone metastases: Incorporating new agents into clinical practice","volume":"6","author":"So A","year":"2012","unstructured":"So A, Chin J, Fleshner N, Saad F. Management of skeletal-related events in patients with advanced prostate cancer and bone metastases: Incorporating new agents into clinical practice. Can Urol Assoc J. 2012, 6:465-70.","journal-title":"Can Urol Assoc J"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-16-1-38","article-title":"The role of the vertebral veins in metastatic processes","volume":"16","author":"Batson OV","year":"1942","unstructured":"Batson OV. The role of the vertebral veins in metastatic processes. Ann Intern Med. 1942, 16:38-45. 10.7326\/0003-4819-16-1-38","journal-title":"Ann Intern Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/ajco.13061","article-title":"Revisiting the role of bone-modifying agents in the management of metastatic prostate cancer","volume":"14 Suppl 5","author":"Cheung FY","year":"2018","unstructured":"Cheung FY. Revisiting the role of bone-modifying agents in the management of metastatic prostate cancer. Asia Pac J Clin Oncol. 2018, 14 Suppl 5:13-5. 10.1111\/ajco.13061","journal-title":"Asia Pac J Clin Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings SR","year":"2009","unstructured":"Cummings SR, San Martin J, McClung MR, et al.. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009, 361:756-65. 10.1056\/NEJMoa0809493","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2147\/BTT.S20677","article-title":"Role of denosumab in the management of skeletal complications in patients with bone metastases from solid tumors","volume":"6","author":"Brown-Glaberman U","year":"2012","unstructured":"Brown-Glaberman U, Stopeck AT. Role of denosumab in the management of skeletal complications in patients with bone metastases from solid tumors. Biologics. 2012, 6:89-99. 10.2147\/BTT.S20677","journal-title":"Biologics"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.08.002","article-title":"Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials","volume":"48","author":"Lipton A","year":"2012","unstructured":"Lipton A, Fizazi K, Stopeck AT, et al.. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer. 2012, 48:3082-92. 10.1016\/j.ejca.2012.08.002","journal-title":"Eur J Cancer"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Fizazi K","year":"2011","unstructured":"Fizazi K, Carducci M, Smith M, et al.. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011, 377:813-22. 10.1016\/S0140-6736(10)62344-6","journal-title":"Lancet"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2020.05.019","article-title":"Denosumab versus zoledronic acid in the prevention of skeletal-related events in vulnerable cancer patients: a meta-analysis of randomized, controlled trials","volume":"42","author":"Chen C","year":"2020","unstructured":"Chen C, Li R, Yang T, et al.. Denosumab versus zoledronic acid in the prevention of skeletal-related events in vulnerable cancer patients: a meta-analysis of randomized, controlled trials. Clin Ther. 2020, 42:1494-1507.e1. 10.1016\/j.clinthera.2020.05.019","journal-title":"Clin Ther"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/ecc.12541","article-title":"Meta-analysis comparing denosumab and zoledronic acid for treatment of bone metastases in patients with advanced solid tumours","volume":"26","author":"Zheng GZ","year":"2017","unstructured":"Zheng GZ, Chang B, Lin FX, et al.. Meta-analysis comparing denosumab and zoledronic acid for treatment of bone metastases in patients with advanced solid tumours. Eur J Cancer Care (Engl). 2017, 26:e12541. 10.1111\/ecc.12541","journal-title":"Eur J Cancer Care (Engl)"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0191455","article-title":"Osteoclast inhibitors to prevent bone metastases in men with high-risk, non-metastatic prostate cancer: a systematic review and meta-analysis","volume":"13","author":"Hayes AR","year":"2018","unstructured":"Hayes AR, Brungs D, Pavlakis N. Osteoclast inhibitors to prevent bone metastases in men with high-risk, non-metastatic prostate cancer: a systematic review and meta-analysis. PLoS One. 2018, 13:e0191455. 10.1371\/journal.pone.0191455","journal-title":"PLoS One"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/cen.14169","article-title":"Hypocalcaemia following denosumab in prostate cancer: a clinical review","volume":"92","author":"Lau LH","year":"2020","unstructured":"Lau LH, Cliff ER, Wong V, et al.. Hypocalcaemia following denosumab in prostate cancer: a clinical review. Clin Endocrinol (Oxf). 2020, 92:495-502. 10.1111\/cen.14169","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.07.016","article-title":"Denosumab for treatment of bone metastases secondary to solid tumours: systematic review and network meta-analysis","volume":"49","author":"Ford JA","year":"2013","unstructured":"Ford JA, Jones R, Elders A, et al.. Denosumab for treatment of bone metastases secondary to solid tumours: systematic review and network meta-analysis. Eur J Cancer. 2013, 49:416-30. 10.1016\/j.ejca.2012.07.016","journal-title":"Eur J Cancer"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2013.813840","article-title":"Incidence and risk of denosumab-related hypocalcemia in cancer patients: a systematic review and pooled analysis of randomized controlled studies","volume":"29","author":"Qi WX","year":"2013","unstructured":"Qi WX, Lin F, He AN, Tang LN, Shen Z, Yao Y. Incidence and risk of denosumab-related hypocalcemia in cancer patients: a systematic review and pooled analysis of randomized controlled studies. Curr Med Res Opin. 2013, 29:1067-73. 10.1185\/03007995.2013.813840","journal-title":"Curr Med Res Opin"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.4172\/2167-0870.1000251","article-title":"Risk factors for hypocalcemia following treatment with denosumab in patients with bone metastases from prostate cancer","volume":"6","author":"Koguchi D","year":"2016","unstructured":"Koguchi D, Satoh T, Tsumura H, et al.. Risk factors for hypocalcemia following treatment with denosumab in patients with bone metastases from prostate cancer. J Clin Trials. 2016, 6:1-7. 10.4172\/2167-0870.1000251","journal-title":"J Clin Trials"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2014.11.008","article-title":"Severe hypocalcemia associated with denosumab in metastatic castration-resistant prostate cancer: risk factors and precautions for treating physicians","volume":"13","author":"Autio KA","year":"2015","unstructured":"Autio KA, Farooki A, Glezerman IG, et al.. Severe hypocalcemia associated with denosumab in metastatic castration-resistant prostate cancer: risk factors and precautions for treating physicians. Clin Genitourin Cancer. 2015, 13:e305-9. 10.1016\/j.clgc.2014.11.008","journal-title":"Clin Genitourin Cancer"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-014-2142-2","article-title":"The effects of denosumab on calcium profiles in advanced cancer patients with bone metastases","volume":"22","author":"Lechner B","year":"2014","unstructured":"Lechner B, DeAngelis C, Jamal N, et al.. The effects of denosumab on calcium profiles in advanced cancer patients with bone metastases. Support Care Cancer. 2014, 22:1765-71. 10.1007\/s00520-014-2142-2","journal-title":"Support Care Cancer"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1177\/1078155216628325","article-title":"Incidence of hypocalcemia in patients receiving denosumab for prevention of skeletal-related events in bone metastasis","volume":"23","author":"Yerram P","year":"2017","unstructured":"Yerram P, Kansagra S, Abdelghany O. Incidence of hypocalcemia in patients receiving denosumab for prevention of skeletal-related events in bone metastasis. J Oncol Pharm Pract. 2017, 23:179-84. 10.1177\/1078155216628325","journal-title":"J Oncol Pharm Pract"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4045","article-title":"Denosumab-associated hypocalcaemia: incidence, severity and patient characteristics in a tertiary hospital setting","volume":"25","author":"Huynh AL","year":"2016","unstructured":"Huynh AL, Baker ST, Stewardson AJ, Johnson DF. Denosumab-associated hypocalcaemia: incidence, severity and patient characteristics in a tertiary hospital setting. Pharmacoepidemiol Drug Saf. 2016, 25:1274-8. 10.1002\/pds.4045","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.1989.tb01423.x","article-title":"The clinical spectrum of hypocalcaemia associated with bone metastases","volume":"226","author":"Riancho JA","year":"1989","unstructured":"Riancho JA, Arjona R, Valle R, Sanz J, Gonz\u00e1lez-Mac\u00edas J. The clinical spectrum of hypocalcaemia associated with bone metastases. J Intern Med. 1989, 226:449-52. 10.1111\/j.1365-2796.1989.tb01423.x","journal-title":"J Intern Med"},{"key":"ref21","article-title":"Severe hypocalcaemia associated with extensive osteoblastic metastases in a patient with prostate cancer","volume":"63","author":"Fokkema MI","year":"2005","unstructured":"Fokkema MI, De Heide LJ, Van Schelven WD, et al.. Severe hypocalcaemia associated with extensive osteoblastic metastases in a patient with prostate cancer. Neth J Med. 2005, 63:34-7.","journal-title":"Neth J Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-018-4533-6","article-title":"Hypocalcemia and bone mineral density changes following denosumab treatment in end-stage renal disease patients: a meta-analysis of observational studies","volume":"29","author":"Thongprayoon C","year":"2018","unstructured":"Thongprayoon C, Acharya P, Acharya C, et al.. Hypocalcemia and bone mineral density changes following denosumab treatment in end-stage renal disease patients: a meta-analysis of observational studies. Osteoporos Int. 2018, 29:1737-45. 10.1007\/s00198-018-4533-6","journal-title":"Osteoporos Int"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1530\/EC-16-0056","article-title":"Society for Endocrinology Endocrine Emergency Guidance: emergency management of acute hypocalcaemia in adult patients","volume":"5","author":"Turner J","year":"2016","unstructured":"Turner J, Gittoes N, Selby P. Society for Endocrinology Endocrine Emergency Guidance: emergency management of acute hypocalcaemia in adult patients. Endocr Connect. 2016, 5:G7-8. 10.1530\/EC-16-0056","journal-title":"Endocr Connect"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-014-2964-2","article-title":"Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: results from a 1-year open-label extension of the Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT)","volume":"26","author":"Sugimoto T","year":"2015","unstructured":"Sugimoto T, Matsumoto T, Hosoi T, et al.. Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: results from a 1-year open-label extension of the Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT). Osteoporos Int. 2015, 26:765-74. 10.1007\/s00198-014-2964-2","journal-title":"Osteoporos Int"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/64660-hypocalcemia-in-a-patient-with-metastatic-prostate-cancer-from-denosumab-treatment","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:33:30Z","timestamp":1707507210000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/64660-hypocalcemia-in-a-patient-with-metastatic-prostate-cancer-from-denosumab-treatment"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,10]]},"references-count":24,"URL":"https:\/\/doi.org\/10.7759\/cureus.17046","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8,10]]}}}